Novartis

The state of the fight: 

A booster dose of Bharat Biotech’s Covaxin increased neutralizing antibodies up to 265-fold.
  WHO added therapies from Eli Lilly and GSK/Vir to its list of recommended Covid-19 treatments.
  Novartis will pay over $162 million to in-license Molecular Partners’ ensovibep antiviral candidate.

 

AUTHORIZED VACCINES

Two doses of Pfizer/BioNTech’s vaccine reduced the risk of Covid-19 hospitalization by 94% among adolescents ages 12…

The state of the fight: 

WHO issued an Emergency Use Listing for Serum Institute of India’s version of Novavax’s vaccine.
  The U.S. CDC recommended mRNA-based vaccines over J&J’s.
  Data on the effectiveness of monoclonal antibody therapies against the Omicron variant began pouring in.

AUTHORIZED VACCINES  

A U.S. CDC advisory panel recommended mRNA-based vaccines over the J&J jab, citing blood clot side effects stemming from the single-dose…

Merck has issued a $1 billion sustainability bond, the company announced Monday. The instrument will fund environmental, social and governance (ESG) projects and “contribute to the advancement of the United Nations Sustainability Development Goals,” according to a press release.

Merck said proceeds from the bond—part of an $8 billion debt offering—will support access to essential healthcare services, infectious disease R&D, socioeconomic advancement and empowerment, renewable…

After more than 20 years as a shareholder, Novartis has agreed to sell its 33% stake in Roche to its Basel-based cross-town rival for $20.7 billion, the companies separately announced last week.

“We concluded that now is the right time to monetize our investment,” Novartis CEO Vas Narasimhan said in a press release. Meanwhile, Roche’s press release claimed the move disentangles the two competitors and enables it to regain “full strategic flexibility.”

Mentions:

Thirteen leading pharma companies released third-quarter 2021 financial results in October, while one Japanese firm reported first-half 2021 results for the fiscal year ending in March. (Figures exclude exchange rate and portfolio changes where applicable.)

South Korea’s LG Chem saw its third-quarter numbers soar 70.7% over the same period last year, delivering $9.1 billion in sales. However, operating profit tumbled 20%, mainly due to a one-off expense associated with its electric…

Novartis has begun a “strategic review” of its Sandoz subsidiary that will “explore all options, ranging from retaining the business to separation,” the Basel-based company announced Tuesday alongside its quarterly earnings statement. While the generic business accounted for around 20% of total company sales last year, the Swiss pharma giant expects the unit’s core operating income to decline more than previously expected, the press release said.

A Wall Street Journal article on…

Mentions:

Novartis’ Sandoz subsidiary will pay $185 million under an agreement with the U.S. government to resolve civil liabilities related to alleged price-fixing of generic drugs, the Department of Justice announced last week. The payment adds to an earlier penalty of $195 million to settle criminal charges in the matter.

The government also announced related civil settlements with Taro Pharmaceuticals (for over $213 million) and Canada-based Apotex (for $49 million). India’s Sun Pharma…

Novartis and Medicines for Malaria Venture (MMV) announced last week positive Phase 2b results for their novel non-artemisinin combination antimalarial. The study tested ganaplacide with a new formulation of lumefantrine optimized for once-daily dosing.

This combination has the potential not only to clear malaria infection, including artemisinin-resistant strains, but also to block the transmission of the malaria parasite, the press release said.

The Journal of Experimental Medicine published Phase 2 results last week showing that Novartis’ enzyme-blocking cancer drug imatinib cleared malaria parasites from 100% of treated adult Vietnamese men in three days when used in combination with standard of care (piperaquine plus dihydroartemisinin).

In contrast, 33% of trial participants who received only standard of care without the imatinib supplement experienced delayed parasite clearance rates—a precursor to and an indicator of…

Mentions:

Thirteen leading pharma companies released second-quarter 2021 financial results in July, while one Japanese firm reported first-quarter results for the fiscal year ending in March. (Figures exclude exchange rate and portfolio changes where applicable.)
 
Pfizer’s revenues soared 86% in the second quarter to $19 billion, beating consensus estimates of $17.5 billion. The Comirnaty Covid-19 vaccine led the results with $7.8 billion in sales. Based on contracts signed through mid-…